Menu
← Oncology Approval Tracker
FDA DECISION ·
Filkri
filgrastim-laha · Accord BioPharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Neupogen biosimilar with labeled cancer uses including febrile-neutropenia risk reduction during myelosuppressive chemotherapy, recovery after AML chemotherapy, and neutropenia support after myeloablative therapy followed by bone marrow transplant.
LAMPGEN ANALYSIS
Why it matters
The approval adds a short-acting growth-factor option across several oncology care settings. Product availability and regimen timing matter for access.
What research teams should watch
Check the labeled indication and route, then match chemotherapy and transplant timing to the supportive-care order. Capture the exact product for safety follow-up.
PRIMARY RECORDS